RENXF (Renalytix) EBIT per Share: $-0.07 (TTM As of Dec. 2025)


What is Renalytix EBIT per Share?

Renalytix RENXF EBIT per Share is $-0.07 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 529 Healthcare Providers & Services companies, Renalytix ranks better than 89.98% on this metric.

Renalytix's EBIT per Share for the six months ended in Dec. 2025 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.07.

During the past 3 years, the average EBIT per Share Growth Rate was 57.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Renalytix's EBIT per Share or its related term are showing as below:

RENXF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -42.7   Med: 10.6   Max: 57.2
Current: 57.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Renalytix was 57.20% per year. The lowest was -42.70% per year. And the median was 10.60% per year.

RENXF's 3-Year EBIT Growth Rate is ranked better than
89.98% of 529 companies
in the Healthcare Providers & Services industry
Industry Median: 12.1 vs RENXF: 57.20

Renalytix's EBIT for the six months ended in Dec. 2025 was $-7.00 Mil.

Renalytix  (OTCPK:RENXF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Renalytix EBIT per Share Related Terms

Renalytix EBIT per Share Historical Data

* Premium members only.

The historical data trend for Renalytix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix EBIT per Share Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial -0.50 -0.72 -0.51 -0.42 -0.08

Renalytix Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -200.90 -0.24 -0.05 -0.05 -0.02

Renalytix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Renalytix's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-21.3/274.580
=-0.08

Renalytix's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-7/382.510
=-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.07 mean?
Renalytix (RENXF) has a EBIT per Share of $-0.07 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #53 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 10%.
Is Renalytix's EBIT per Share too high?
Renalytix's current EBIT per Share is $-0.07. Based on the distribution chart, Renalytix ranks #53 out of 529 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Renalytix's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #53 out of 529 companies for EBIT per Share. This places Renalytix in the top 10% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current EBIT per Share is $-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 39.8% below its estimated fair value. The current EBIT per Share is $-0.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Renalytix (RENXF), the current EBIT per Share is $-0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renalytix Business Description

Other Exchanges RENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.